Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — IPO Roadshow (June 2016)
25 slides from Inspiremd's IPO roadshow presentation, Jun 10, 2016
Slide 1: InspireMD Issuer Free Writing Prospectus, June 2016
NYSE MKT: NSPR June 2016 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Registration Statement No. 333 - 210760
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward - looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward - lo
Slide 3: Free Writing Prospectus
Free Writing Prospectus 3 This presentation highlights basic information about InspireMD, Inc. and the offering. InspireMD, Inc. has filed a registration statement on Form S - 1 (Registration No. 333 - 210760) (including a prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for
Slide 4: InspireMD
InspireMD Pioneering fully integrated embolic prevention systems and other advanced medical technology for vascular procedures NYSE MKT: NSPR Stock Price (5/31/16): $0.465 52 Week Range: $0.32 - $4.20 Average Volume: 89K Shares Outstanding (5/31/16): 10.7 M Market Capitalization (5/31/16): $4.98 M A
Slide 5: Investment Highlights
Investment Highlights • 2016 focus on revenue growth driven by a broader EU launch of CGuard • Strategic distribution partnership with Penumbra (NYSE:PEN) • Significant growth in Italy over the last 3 quarters serving as a leading indicator • Positive clinical trial results using CGuard in a broad p
Slide 6: The Problem
The Problem Embolization can lead to catastrophic health events 6
Slide 7: Embolization following Carotid Artery Stenting
Embolization following Carotid Artery Stenting “Plaque protrusion through stent struts occurs in up to 65.5% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization , either
Slide 8: Pre-Procedure vs Post-Procedure
Pre - Procedure Post - Procedure Cano et al. Rev Bras Cardiol Invasiva 2013; 21(2): 159 - 64 A. Pre - intervention showing 90% occlusion of the carotid artery and an MRI showing an old white matter infarction (obstruction). B. Post - intervention showing successful opening of the occluded carotid ar
Slide 9: MicroNet
MicroNet™ • Provides revascularization benefit • MicroNet acts as “safety net” by offering greater vessel area coverage to prevent large debris flow through the scaffold • Made of a single fiber from a biocompatible polymer, widely used in other medical implants Proprietary technology for preventing
Slide 10: Large Addressable Market Expanding the MicroNet Platform
Large Addressable Market Expanding the MicroNet™ Platform MGuard™* x $1.7B AMI Market x CE Mark Cleared x Coronary AMI, SVG CGuard ™ x $500M Market x CE Mark Cleared x FDA IDE draft protocol synopsis x Carotid NGuard x $125M Flow Diversion Market x $550M Aneurysm Market x 2017E CE Mark Planned Submi
Slide 11: CGuard Embolic Prevention System (EPS)
CGuard™ Embolic Prevention System(EPS) Combines stent and embolic protection in a single device *Source : JMP Securities, 2014 and Cowen 2014. Carotid Solution: Mesh Covered Technology • CE marked • Self - expanding nitinol stent • Global market valued at $500M* • Positive CARENET data released 9/14
Slide 12: CARENET Clinical Trial
CARENET Clinical Trial • 30 Patient Safety and Efficacy clinical trial • Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%*) • 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical non - mesh carotid artery stenting da
Slide 13: Carotid Market Opportunity
“The most important theme during [EuroPCR 2016] was carotid artery stenting….[The double layered mesh stents] will resolve the main problem of carotid artery stents which was late embolic events.” A. Cremonesi Carotid Market Opportunity • Current standard of care: S urgery • Carotid Endarterectomy (
Slide 14: Strategic Distribution Partnership
Strategic Distribution Partnership • D istribution agreement with Penumbra • 18 European markets with opportunity to expand • Comprehensive neurovascular product portfolio • CGuard is a synergistic product offering • Growing direct sales force throughout Europe • Establishing a direct sales force fo
Slide 15: CGuard Distribution (EU)
CGuard Distribution (EU) 15 Penumbra (Direct) 18 Countries InspireMD or Distributor E E
Slide 16: CGuard Country Case Study: Italy
CGuard™ Country Case Study • CGuard covered by 2 distributors • Initial success drove 29 I talian carotid interventionalists to initiate the IRON - Guard* registry last year - 20 40 60 80 100 120 140 160 Q1 15 Q2 Q3 Q4 Q1 16 Italy CGuard Revenue Note: Revenue in $000’s Italy – A leading indicator of
Slide 17: Robust Pipeline Expanding Indications with MicroNet
Commercial • CE Mark Cleared • 12 - month MASTER I, II MicroNet ™ Platform Technology MGuard ™ Coronary EPS NGuard ™ Neurovascular* RGuard™ Renal * CGuard ™ Carotid PVGuard™ Peripheral * MGuard ™ Drug Eluting * * Planning & Development Phase Commercial • CE Mark Cleared • CARENET Trial • PARADIGM al
Slide 18: Neurovascular Market Opportunity
Neurovascular Market Opportunity Innovation leads growth * 2013 MRG Neuro Report, 2010 Ev3 Revenue Data ** 2014 projection based on 2013 actuals 2014 Competitive Landscape: Relatively Fewer Players Product Company Approval Pipeline Medtronic/Covidien CE Mark 2014 FDA 2011 Surpass Stryker CE Mark 201
Slide 19: Neurovascular Aneurysms
Neurovascular Aneurysms Objective • Seal the aneurysm and prevent rupture Current device therapies • Coils to pack the aneurysm • Flow diverters • Highly flexible, dense metal “tube” • Placed in main artery to seal off aneurysm and cause aneurysm thrombosis • Precise delivery required to avoid block
Slide 20: InspireMD Flow Diverter Advantage
InspireMD Flow Diverter Advantage • Low profile, flexible, open cell scaffold = Easy to delivery • Low metal ratio = Potential for reduced anti - thrombosis medication • Re - accessible through MicroNet™ = Allows for further treatment, if needed which is impossible with current flow diverters • Can
Slide 21: Intellectual Property Portfolio
Intellectual Property Portfolio Continue to strengthen and broaden patent protection globally. Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products. 21 PATENT RIGHTS Issued Allowed Pending US 4 0 11 Rest of World (ROW) 16
Slide 22: Executive Team and Board of Directors
EXECUTIVE TEAM BOARD OF DIRECTORS Dr. James Barry, President and CEO • Boston Scientific • Howmedica Division of Pfizer Craig Shore, CFO • Pfizer • General Electric David Blossom, VP Global Marketing & Strategy • Boston Scientific • Covidien Dr. Sol Barer, Chairman • Former Chairman and CEO, Celgene
Slide 23: Use of Proceeds
Use of Proceeds • Commercial Execution of CGuard™ and MGuard™ EPS • Development of NGuard ™ Flow Diverter through CE submission • Working Capital • General Corporate Purposes 23
Slide 24: Investment Highlights
Investment Highlights • 2016 focus on revenue growth driven by a broader EU launch of CGuard • Strategic distribution partnership with Penumbra (NYSE:PEN) • Significant growth in Italy over the last 3 quarters serving as a leading indicator • Positive clinical trial results using CGuard in a broad p
Slide 25: Contact: James Barry and Craig Shore
James Barry, Ph.D., President and CEO 888.776 . 6804 jimb@inspiremd.com Craig Shore, CFO 888.776 . 6804 craigs@inspiremd.com